Clinical Judgment Versus Biomarker Prostate Cancer Gene 3: Which Is Best When Determining the Need for Repeat Prostate Biopsy?
Bertrand Tombal(Cliniques Universitaires Saint-Luc), Herman Stoevelaar(Barnes-Jewish Hospital), Paolo Gontero(Fondazione Ricerca Molinette), Gerald L. Andriole(Institut thématique Génétique, génomique et bioinformatique), Louis Smets, Alexander Haese(Universität Hamburg), Mark Speakman(Taunton & Somerset NHS Foundation Trust), Alexandre de la Taille(Centre Hospitalier Universitaire Henri-Mondor), Mesut Remzi(Landesklinikum Korneuburg)
Cited by 32
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
|Nature Genetics|2007|1.1k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
|Controlled Clinical Trials|2000|1k